Autopsy report · NCT00508157
A Phase 4 Study to Assess the Effects of Aripiprazole Versus Other Atypical Antipsychotics in the Treatment of Schizophrenic Patients With Metabolic Syndrome
Cause of deathSlow enrollment
“Slow Accrual”
Life of this trial
- Registered 4 months before it started.
- Ran for about 1 year 4 months before it stopped.
- 125 participants enrolled.
- Results were posted on the registry 1 year 4 months after it ended.
Vital statistics
- Status
- Terminated
- Phase
- Phase 4
- Sponsor
- Bristol-Myers Squibb
- Sponsor type
- Industry
- Conditions
- Metabolic Syndrome; Schizophrenia
- Interventions
- Aripiprazole; Continued Antipsychotic (Risperidone or Quetiapine or Olanzapine)
- Participants
- 125
- Sites
- 30
- Countries
- Belgium, Czechia, France, Germany, Greece, Hungary, Spain, Switzerland, Turkey (Türkiye)
Look deeper
- The official registry record (the source of truth)
- Record history: every change the sponsor made
- Open it in the database
Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.